PV Bulletin

Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling

FDA issued draft guidance providing recommendations for studies assessing pharmacokinetics in patients with hepatic impairment.

Primary source: Download the Draft Guidance Document

PV Impact Brief

MonitoringConfidence: high

What changed

The FDA has proposed recommendations that pharmacokinetic studies should be conducted for drugs if hepatic metabolism or excretion accounts for more than 30% of the elimination of the drug.

Why it matters

This guidance affects how pharmaceutical companies design studies and label drugs, ensuring that dosing is appropriate for patients with liver impairment, thereby enhancing patient safety and compliance.

Action needed

Pharmaceutical companies should prepare to assess the impact of hepatic impairment early in drug development, particularly for drugs that require pharmacokinetic assessments.

Relevant for
Regulatory Intelligence LeadLabeling Lead
Processes impacted
LabelingSignal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 31, 2026

Full briefing

Practical implication

Pharmaceutical companies should prepare to assess the impact of hepatic impairment early in drug development, particularly for drugs that require pharmacokinetic assessments.

The FDA has released draft guidance that outlines the study design and data analysis methods for evaluating pharmacokinetics in patients with impaired hepatic function. The guidance is not for implementation yet, and it encourages sponsors to consider the influence of hepatic impairment on dosing and labeling of drugs.

What changed: The FDA has proposed recommendations that pharmacokinetic studies should be conducted for drugs if hepatic metabolism or excretion accounts for more than 30% of the elimination of the drug.

Why it matters: This guidance affects how pharmaceutical companies design studies and label drugs, ensuring that dosing is appropriate for patients with liver impairment, thereby enhancing patient safety and compliance.

Practical implication: Pharmaceutical companies should prepare to assess the impact of hepatic impairment early in drug development, particularly for drugs that require pharmacokinetic assessments.

View original source

  • Source: FDA - Regulatory Information
  • Published at source: 2026-08-31T00:00:00.000Z
  • Discovered by monitor: 2026-09-01T22:08:08.419Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward